achey node
Greenlighter
- Joined
- Jan 24, 2014
- Messages
- 6
Given that mental illness is characterised by a disorder in one or more brain systems it is quite contradictory that the endogenous opioid system and in particular the mu opioid recpetor and its native agonists are ignored. Prolific serotonin reuptake and monoamine oxidation both result in the presentationof depressive symptoms but there is no scientific model that I know of describing the same situation at the mu opioid receptor site.
I vaguely remember that Effexor or some similar SNRI has been identified as binding to receptor sites but overall medical orthodoxy seems to lack the courage to remedy disorders of the opioid system.
What is the current state of affairs regarding this and are there any long term non neurotoxic/sustainable opioid derivatives which can prevent attenuating factors in endorphin production and longevity.
I vaguely remember that Effexor or some similar SNRI has been identified as binding to receptor sites but overall medical orthodoxy seems to lack the courage to remedy disorders of the opioid system.
What is the current state of affairs regarding this and are there any long term non neurotoxic/sustainable opioid derivatives which can prevent attenuating factors in endorphin production and longevity.
Last edited:
